maleamic acid has been researched along with osteoprotegerin in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Fischer, T; Fukuda, N; Honma, M; Höpner, U; Ikeda, T; Kasuya, Y; Kurihara, A; Mochizuki, S; Mueller, J; Nagayama, Y; Okada, A; Okada, F; Okada, J; Okazaki, O; Saito-Yabe, M; Suzuki, Y; Tsuda, E; Yamamura, N; Yano, K; Yoshigae, Y; Zaja, S | 1 |
| Furuta, Y; Higaki, K; Izumi, T; Kasuya, Y; Kurihara, A; Miyaji, Y; Ogawara, K; Okazaki, O; Takahashi, M | 1 |
2 other study(ies) available for maleamic acid and osteoprotegerin
| Article | Year |
|---|---|
PEGylation of osteoprotegerin/osteoclastogenesis inhibitory factor (OPG/OCIF) results in decreased uptake into rats and human liver.
Topics: Animals; Biological Transport; Bone Density Conservation Agents; Cells, Cultured; Chemistry, Pharmaceutical; Down-Regulation; Enzyme-Linked Immunosorbent Assay; Female; Heparin; Humans; Injections, Intravenous; Kidney; Liver; Maleates; Mice; Osteoclasts; Osteoprotegerin; Ovariectomy; Perfusion; Polyethylene Glycols; Rats; Rats, Sprague-Dawley; Spleen; Tissue Distribution | 2010 |
Novel comb-shaped PEG modification enhances the osteoclastic inhibitory effect and bone delivery of osteoprotegerin after intravenous administration in ovariectomized rats.
Topics: Administration, Intravenous; Animals; Bone and Bones; Bone Marrow; Bone Resorption; Drug Carriers; Drug Delivery Systems; Female; Humans; Maleates; Osteoclasts; Osteoprotegerin; Ovariectomy; Polyethylene Glycols; Polymers; Rats; Rats, Inbred F344; Recombinant Proteins; Structure-Activity Relationship; Tissue Distribution | 2012 |